Novartis buys IFM unit, picking up STING inhibitors

13 Mar 2024
www.pharmamanufacturing.com
Acquisition
Novartis has exercised its option to acquire all the outstanding capital stock of IFM Due, a subsidiary of Boston-based IFM Therapeutics.
IFM Due and Novartis entered into an option and collaboration agreement back in September 2019. Now, per the deal, IFM will receive $90 million upfront and will be eligible for up to $745 million in milestone payments, adding up to $835 million in total consideration.
IFM Due was launched in February 2019, with a focus on developing small molecules that inhibit the cGAS-STING pathway. The recent acquisition provides Novartis with full rights to IFM Due’s portfolio of STING antagonists, which have the potential to treat an array of serious inflammation-driven diseases characterized by excessive interferon and other pro-inflammatory cytokine signaling.
This is Novartis' second acquisition of an IFM Therapeutics subsidiary. In April 2019 Novartis paid  $310 million upfront for subsidiary IFM Tre, shortly after Tre had dosed an initial subject with its first-in-class NLRP3 antagonist, IFM-2427. The molecule was the first of Tre's three unique development candidates to enter the clinic, all of which are intended to block only the inflammation driven by the NLRP3 pathway.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.